LONDON--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc (“Morria”), an anti-inflammatory drug development company, announced today that its has successfully completed a financing round raising £1.6 million through private placing of 2,000,000 Ordinary Shares at a price of £0.80 per share. The round was led by its Financial Consultants Charles Street Securities, Inc. (CSS) of London.
